Insight

William Oh: Better biology and new targeted therapies is driving more benefit for patients, but there is still a long way to go

William Oh/Linkedin

Dec 2, 2023, 16:55

William Oh: Better biology and new targeted therapies is driving more benefit for patients, but there is still a long way to go

William Oh, Chief Medical Officer at the Prostate Cancer Foundation (PCF), shared on LinkedIn:

“MSK-IMPACT has been a key single source of data regarding the growing influence of precision medicine in cancer. From 2017- 2022, an increase was noted from 8.9% to 31.6% in the fraction of tumors harboring a standard care (Level 1 or 2) predictive biomarker of therapy response and an almost halving of tumors carrying non-actionable drivers (44.2% to 22.8%). Better biology and new targeted therapies is driving more benefit for patients, but there is still a long way to go.”

For the article click here.
Source: William Oh/LinkedIn

cancer Memorial Sloan Kettering Cancer Center (MSK) MSK-IMPACT OncoDaily Oncology Precision Medicine Prostate Cancer Foundation Target therapy William Oh

Esophageal Cancer: Symptoms, Causes, Stages, Diagnosis & Treatment

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Special Coverage